Skip to Content

Ergocalciferol Disease Interactions

There are 6 disease interactions with ergocalciferol:

Major

Amine ergots (Includes ergocalciferol) ↔ cardiovascular adverse effects

Severe Potential Hazard, Moderate plausibility. Applies to: Tachyarrhythmia

The amine ergot alkaloids, ergonovine and methylergonovine, can cause serious cardiovascular complications because of their vasospastic effects. Hypertension (more often with ergonovine) has been most commonly reported, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors. Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes. Other, less common adverse effects include acute myocardial infarction, transient chest pains, thrombophlebitis, tachycardia and palpitations. Therapy with ergot alkaloids should generally be avoided, except under special circumstances, in patients with chronic hypertension, preeclampsia or eclampsia, cardiovascular disease, cerebrovascular disease, or peripheral vascular disease. Caution is advised when these agents are administered to patients with venoatrial shunts, mitral valve stenosis, or sepsis. Close monitoring of cardiovascular status is highly recommended during therapy.

References

  1. "Product Information. Ergotrate Maleate (ergonovine)." Bedford, Bedford, OH.
  2. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
Major

Vitamin D analogs (Includes ergocalciferol) ↔ arrhythmia

Severe Potential Hazard, High plausibility. Applies to: Arrhythmias

Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides. Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias. Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.

References

  1. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories, Nutley, NJ.
  2. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma, Mequon, WI.
  3. "Product Information. Calderol (calcifediol)." Organon, West Orange, NJ.
Major

Vitamin D analogs (Includes ergocalciferol) ↔ electrolyte imbalance

Severe Potential Hazard, High plausibility. Applies to: Phosphate Imbalance

Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or renal systems or other soft tissue calcifications. A solubility product (Serum Calcium X Phosphate) should not exceed 70. Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.

References

  1. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma, Mequon, WI.
  2. "Product Information. Calderol (calcifediol)." Organon, West Orange, NJ.
  3. "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical, Abbott Park, IL.
  4. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories, Nutley, NJ.
View all 4 references
Major

Vitamin D analogs (Includes ergocalciferol) ↔ hypercalcemia

Severe Potential Hazard, Moderate plausibility. Applies to: Hypercalcemia, Malabsorption Syndrome

Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.

Major

Vitamin D analogs (Includes ergocalciferol) ↔ renal dysfunction

Severe Potential Hazard, High plausibility. Applies to: Renal Dysfunction

Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation. Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.

References

  1. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma, Mequon, WI.
  2. "Product Information. Calderol (calcifediol)." Organon, West Orange, NJ.
  3. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories, Nutley, NJ.
Moderate

Vitamin D analogs (Includes ergocalciferol) ↔ hepatobiliary dysfunction

Moderate Potential Hazard, High plausibility. Applies to: Biliary Obstruction, Liver Disease

Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs. Metabolites of vitamin D analogs are primarily excreted in bile and feces. Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation. Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.

References

  1. "Product Information. Calderol (calcifediol)." Organon, West Orange, NJ.
  2. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma, Mequon, WI.
  3. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories, Nutley, NJ.

Ergocalciferol drug interactions

There are 165 drug interactions with ergocalciferol

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide